Inspiration I've heard of using live bacteria for tissue specific drug transfer. But the bacteria cannot survive for long because of the unstable interaction between the host and the prokaryote. What i was working on was some ways to stabilize this interaction in such a way that both parties are benefitted. DFU treatment is just one of it's hundreds of applications which i see
What it does. Specific to different types of DFU(neuropathy,microangiopathy,macroangiopathy), we are modifying the bacteria for treating DFU and potentially curing it, which is almost impossible with any of the currently used medication methos
How we built it. In the document
Challenges we ran into. Even though it offers a large chance of curing microangiopathy, macroangiopathy remained a big problem. This method with the help of some more complex genetic modification can potentially cure it with proper research and implementation. The major challenges were the following questions, 1)will the bacteria turn infectious as diabetes patients have lower immune response - No because of the lack of DAP and thymidine gene it cannot live for long in an external system,2) Will the nutrient medium for L.plantarum helps other infective bacteria in the wound to grow - We are mostly providing DAP in the nutrient medium, also a small antibiotic therapy before applying the product can be done to reduce such chances
Accomplishments that we're proud of. I strongly believe that even though this method's initial investment is high(500$ - 20,000$), the income after commercializing it, will cover it. The product can be made available with a cost of0.5$ - 3$.
What we learned. Learned how to create prototypes specific to certain types of DFU
What's next for Diabetes Foot Ulcer Treatment using induced Symbiosis. Using ML or Dl to make the detection much more faster and accurate by supplying the data from the product
Log in or sign up for Devpost to join the conversation.